Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138162 | 0.96 | PROKR1 (0.35) | CCNT1CDK9MAP3K12BRD4 | |
| SCHEMBL20138016 | 0.85 | LMNA (0.34) | PDE4B | |
| SCHEMBL20137992 | 0.84 | TSHR (0.37) | CCNT1CDK9MAP3K12PRMT5TSHR | |
| SCHEMBL18304954 | 0.83 | PROKR1 (0.35) | CCNT1CDK9MAP3K12BRD4KMT2A | |
| SCHEMBL28537853 | 0.81 | BRD4 (0.36) | CCNT1CDK9BTKPDE4BBRD4 | |
| SCHEMBL20137925 | 0.80 | KCNK3 (0.36) | BRD4NPC1MAPTRAB9AKMT2A | |
| SCHEMBL20138149 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL20137972 | 0.78 | SLC2A1 (0.30) | — | |
| SCHEMBL28535412 | 0.77 | BRD4 (0.39) | CCNT1CDK9MAP3K12BRD4 | |
| SCHEMBL20138178 | 0.77 | RBP4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | CCNT1 4837/4885CDK9 2737/4885MAP3K12 473/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | CCNT1 4373/4885CDK9 2310/4885MAP3K12 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.